Increase in Diagnostic Applications Expected to Drive Global Biomarker Market over the Forecast Period: Ken Research
Biomarker is a biological molecule, measured in biological samples for instance blood, urine and saliva. It is used to effectively & accurately evaluate pharmacologic responses, biological procedures and pathogenic procedures. It is also known as signature molecule or molecular marker. Various biomarkers are available for biological systems such as cardiovascular system, immune system and metabolic system. It is also used to detect, predict disease vulnerability and monitor disease progression for infectious diseases, metabolic diseases, cancer, central nervous system disease and autoimmune diseases.
According to study, “Global Biomarker Market Size study, by Disease Indication (Cancer, Cardiovascular Disorder, Infectious Diseases, Neurological Disorder, Immunological Disorder, Others), by Application (Diagnosis, Drug Discovery and Development, Others), by End-Use (Hospitals, Research Laboratories, Ambulatory Surgical Centers, Diagnostic Laboratories), by Product Type (Biomarker Test Kits, Biomarker Analyzers) and Regional Forecasts 2018-2025” the key companies operating in the global biomarker market are Abbott Laboratories Inc., BG Medicine Inc., Medtronic, Siemens Healthcare GmbH, F. Hoffmann LA Roche Ltd., Qiagen N.V., Nexus-DX, Lifesign LLC, 23andMe, Aushon BioSystem Inc., Merck & Co. Inc., Thermo Fisher Scientific Inc., Roche Diagnostics Ltd., PerkinElmer Inc., Enzo BIochem Inc., Eisai Co. Ltd., Bio-Rad Laboratories Inc., EKF Diagnostics Holdings, Inc., Biosims Technologies Sas, G.E. Healthcare Inc., Meso Scale Diagnostics, LLC., Agilent Technologies Inc., Signosis, Inc., Epistem Ltd., Cisbio Bioassays, Ambry Genetics, Quest Diagnostics, Biomerieux, Illumina, Inc., Hologic, Inc. The key vendors are developing novel kits & therapies or drugs to target population in the areas with high unmet clinical needs.
Based on type, biomarker market is segmented into safety biomarkers, validation biomarkers and efficacy biomarkers. Efficacy biomarkers are further sub-segmented into surrogate biomarkers, predictive biomarkers, prognostic biomarkers and pharmacodynamic biomarkers. Based on disease indication, market is segmented into cancer, cardiovascular disorders, neurological disorders, immunological disorders and others (renal disorders, diabetes, urinal diseases, and tuberculosis). Based on services, market is segmented into tests, drug discovery, therapies, drug formulation and others. Based on profiling technologies, market is segmented into OMICS technology, immunoassays, imaging technology, bioinformatics and cytogenetics. OMICS technology is further sub-segmented proteomics, transcriptomics, genomics, and metabolomics. Imaging technology is further sub-segmented into Positron Emission Tomography (PET), ultrasound, Single-Photon Emission Computed Tomography (SPECT), Computed Tomography (CT) and magnetic resonance imaging (MRI). Additionally, bioinformatics segment is further sub-segmented into data mining, cluster analysis, cell signal pathways, statistical analysis, computer aided design, and protein interaction maps. In addition, based on application, market is segmented into disease diagnosis, risk assessment, development of molecular diagnostic, drug discovery & development, forensic application, drug formulation, DNA fingerprinting and others.
The biomarker market is driven by increase in diagnostic applications of biomarkers (companion diagnostics and personalized medicine), followed by high prevalence of cancer, rise in R&D funding for pharma & biotech companies, higher adoption rate of biomarkers technologies, increase in number of CROs & low cost of clinical trials in developing countries and new initiatives for biomarker research. However, poorly suited regulatory & reimbursement systems, high capital investments & low cost-benefit ratio and technical issues related to sample collection and storage may impact the market. Moreover, increase in demand of personalized medicine and growth in importance of companion diagnostics are key opportunities for market.
Based on geography, the North-American region dominates the biomarker market of biomarkers owing to rise in demand of aging population for diagnosis and treatment of age related diseases in the region. The Asian-pacific region is expected to witness high growth rates due to increase in research and development (R&D) activities and rise in number of contract research organizations over the forecast period.
For more information, refer to below link:-
Ankur Gupta, Head Marketing & Communications